Grade 3 and grade 4 cutaneous toxicities in patients with multiple solid tumour types receiving checkpoint inhibitor therapy: an observational study. The experience of a single large specialist institution
Severe cutaneous toxicities can result in the discontinuation of ICI therapy. Early recognition of severe cutaneous toxicity is necessary to balance effective management of skin toxicity with continued cancer control.
Authors
- Kara Heelan (ORCID: https://orcid.org/0000-0001-9527-0844)
- Praveena Idaikkadar (ORCID: https://orcid.org/0000-0002-4029-7633)
- Zain Sharif (ORCID: https://orcid.org/0000-0003-4635-5862)
- Lisa M. Pickering (ORCID: https://orcid.org/0000-0002-7579-340X)
- Nadza Tokaca (ORCID: https://orcid.org/0000-0001-7825-4404)
- Alicia Okines (ORCID: https://orcid.org/0000-0002-2068-2593)
- James Larkin (ORCID: https://orcid.org/0000-0001-5569-9523)
- Silvia Aguilar-Durán (ORCID: https://orcid.org/0000-0002-2204-5555)
- Kate Young (ORCID: https://orcid.org/0000-0002-9500-2046)
Institutions
- Royal Marsden NHS Foundation Trust (GB)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1093/ced/llaf173
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.18